A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Novartis
University of Chicago
Cho Pharma Inc.
National Institutes of Health Clinical Center (CC)
CellCentric Ltd.
Incyte Corporation
National Cancer Institute (NCI)
University of California, Davis
Acerta Pharma BV
University of Cologne
Genmab
Celgene
Celgene
International Extranodal Lymphoma Study Group (IELSG)
Memorial Sloan Kettering Cancer Center
Celgene
University of Nebraska
University of Nebraska
University of Wisconsin, Madison
Celgene
TG Therapeutics, Inc.
TG Therapeutics, Inc.
The First Affiliated Hospital with Nanjing Medical University
Takeda
Merck Sharp & Dohme LLC
NYU Langone Health
Institut Paoli-Calmettes
M.D. Anderson Cancer Center
Celgene
Celgene
Celgene
National Cancer Institute (NCI)
Celgene
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Celgene
Mayo Clinic
Celgene
Case Comprehensive Cancer Center
Georgetown University
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Celgene